Moderna COVID-19 Shot Is 93% Effective After Six Months Of Second Dose

Trending Investment Opportunities

Moderna Inc's MRNA COVID-19 vaccine continues to be 93% effective six months after the second dose, the Company reported in its Q2 earnings release.
The number shows that efficacy "remains durable" through that time and hardly wanes from the 94.5% efficacy Moderna reported last November.
By comparison, Pfizer Inc PFE and BioNTech SE BNTX said their vaccine efficacy declined to around 84% after six months.
"We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat, so we must remain vigilant," Moderna CEO Stéphane Bancel said.
Moderna said that candidates who received a booster shot during a phase 2 trial produced "robust antibody responses" against the Delta and Gamma variants.
"Given this intersection, we believe dose 3 booster will likely be necessary before the winter season," Moderna wrote, per CNBC.
Bancel said that the Company is working to create "a single dose annual booster" that protects adults against the virus, the flu, and the respiratory syncytial virus.
Related: Moderna Sold Less Than Expected mRNA COVID-19 Vaccine Jabs In Q2; Sees $20B In FY21 Product Sales.
Price Action: MRNA shares are down 1.34% at $413.67 during the market session on the last check Thursday.
Image by Spencer Davis from Pixabay